Metformin use and the risk of liver cancer in a Swedish population-based cohort study
JNCI Cancer Spectrum · 2026
DOI: 10.1093/jncics/pkag053 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Yongying Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Metformin, Liver Neoplasms, Hypoglycemic Agents, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Swedish Cancer Society.
Abstract (Originalsprache)
Background
It is uncertain whether medication with metformin decreases the risk of liver cancer. This study aimed to test the hypotheses that use of metformin decreases the risk of developing both main subtypes of liver cancer, that is, hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Methods
This nationwide population-based cohort study included all individuals who had dispensed anti-diabetic medications between 2005 and 2018 in Sweden, except for those with a history of viral hepatitis. We assessed the associations between metformin use and the risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by using Cox regression, adjusted for age, sex, calendar year, smoking-related diagnoses, alcohol-related diagnoses, non-alcoholic fatty liver disease, use of non-steroidal anti-inflammatory drugs, and use of statins.
Results
Among 744 173 participants, 526 859 (70.8%) were metformin users. During the follow-up of a median of 6.8 (maximum 13.5) years, 1622 participants developed hepatocellular carcinoma and 319 developed intrahepatic cholangiocarcinoma. Metformin use was associated with a slightly increased risk of hepatocellular carcinoma (hazard ratio [HR] = 1.15, 95% confidence interval [CI] = 1.02 to 1.30), but a decreased risk in participants with a prior diagnosis of obesity (HR = 0.56, 95% CI = 0.34 to 0.90). No statistically significant association was observed for intrahepatic cholangiocarcinoma (HR = 0.77, 95% CI = 0.59 to 1.01).
Conclusion
This study found an increased risk of hepatocellular carcinoma associated with metformin use overall, while suggesting a decreased risk in individuals with obesity. No clear association was observed for intrahepatic cholangiocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
- School of Public Health, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Yongying Huang, Shao-Hua Xie
Förderung
- Wellcome Trust
- Swedish Cancer Society
Zitieren
APA
Huang, Y., Santoni, G., Sparrelid, E., & Xie, S. H. (2026). Metformin use and the risk of liver cancer in a Swedish population-based cohort study. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag053
Vancouver
Huang Y, Santoni G, Sparrelid E, Xie SH. Metformin use and the risk of liver cancer in a Swedish population-based cohort study. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag053
BibTeX
@article{Huang2026,
author = {Huang, Yongying and Santoni, Giola and Sparrelid, Ernesto and Xie, Shao-Hua},
title = {Metformin use and the risk of liver cancer in a Swedish population-based cohort study},
journal = {JNCI Cancer Spectrum},
year = {2026},
doi = {10.1093/jncics/pkag053}
}
EUVIMED